Table A2.10Posterior summaries of the absolute response rate for second-line treatment (in bold) as part of a sequence of treatments (median with 95% credible interval)

TreatmentAbsolute response rate (95% CrI)
FOLFOX/XELOX then FOLFIRI/XELIRI (reference)0.04 (0.01, 0.12)
FOLFOX/XELOX then irinotecan0.12 (0.04, 0.29)
FOLFIRI/XELIRI then FOLFOX/XELOX0.14 (0.06, 0.28)

From: Appendix 2, Mixed treatment comparison and cost-effectiveness analysis for sequences of oxaliplatin and irinotecan-based chemotherapy in the treatment of advanced and metastatic colorectal cancer

Cover of Colorectal Cancer
Colorectal Cancer: The Diagnosis and Management of Colorectal Cancer.
NICE Clinical Guidelines, No. 131.
National Collaborating Centre for Cancer (UK).
Copyright © 2011, National Collaborating Centre for Cancer.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.